


Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus

Dorota Suszek¹ , Maciej Dubaj², Karol Bigosiński², Aleksandra Dembowska², Marcin Kaniewski², Wiktoria Sielwanowska², Bartosz Skierkowski², Izabela Dzikowska², Julia Sieczka², Maria Majdan¹

¹Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland

²Student Scientific Circle at the Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high heterogeneity of clinical manifestations and an uncertain prognosis. Although the mortality rate due to SLE has decreased significantly in recent decades, there is still a need to find good tools to measure disease activity for early detection of exacerbations and treatment planning. Over the decades, more than a dozen disease activity scales/indicators have been developed, with the SLE Disease Activity Index (SLEDAI) being the most popular. More recently, the new SLE Disease Activity Score (SLE-DAS) has been introduced. This paper compares the two methods of assessing SLE activity, and presents the relevance of these scales in pregnant SLE patients and their use in formulating definitions of remission and low disease activity. The results show that the SLEDAI and the SLE-DAS are of comparable value in assessing SLE activity and complement each other.

Key words: SLE, SLEDAI, activity scales, SLE-DAS.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that manifests with a variety of clinical symptoms and abnormalities in laboratory tests. The course of the disease is progressive and can lead to irreversible organ damage and death of the patient [1]. Early diagnosis of SLE and effective treatment tailored to disease activity are important in improving prognosis. A well-conducted activity assessment makes it possible to distinguish between SLE symptoms resulting from its exacerbation and chronic damage, which may be a consequence of the disease itself, comorbidities or the treatment used [2, 3]. The current approach to treating SLE patients is the treat-to-target strategy (T2T), commonly

used in rheumatic diseases. A key element of this strategy is defining the treatment goal and reliably assessing SLE activity, which will allow good therapy planning and consequently achieving the desired goal of remission or low disease activity [4]. Various tools have been developed to assess activity and organ damage in SLE patients, including the British Isles Lupus Assessment Group (BILAG) scale, the Easy-BILAG, the European Consensus Lupus Activity Measurements (ECLAM), the Systemic Lupus Activity Measure (SLAM), the SLE Disease Activity Index (SLEDAI), the SLE Disease Activity Score (SLE-DAS), the Physician Global Assessment (PGA) and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) [5–7]. Based

Address for correspondence:

Dorota Suszek, Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University, 8 Jaczewskiego St., 20-954 Lublin, Poland, tel. +48 81 724 47 90, fax: +48 81 724 45 15, e-mail: suszekdorota@wp.pl

Received: 21.05.2024; Accepted: 12.06.2024

on selected activity scales, criteria for low SLE activity – the Lupus Low Disease Activity State (LLDAS) criteria, and disease remission – the Definitions Of Remission In SLE (DORIS) criteria, have been established [8–10].

Systemic Lupus Erythematosus Disease Activity Index and its modifications

First published in 1992, the SLEDAI scale has become a common tool for assessing SLE activity. Several modifications of this scale have been developed over the past few years, including: the SLE Disease Activity Index 2000 (SLEDAI-2K), the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA-SLEDAI), and the Mexican Modification of the Systemic Lupus Erythematosus Disease Activity Index (Mex-SLEDAI) [11–13]. One of the most widely used modifications is the SLEDAI-2K scale, developed in 2002. The scale's questionnaire contains 24 clinical symptoms, of which 16 are clinical and 8 are based on laboratory findings. A given symptom is considered present if it occurs regardless of its severity. In the original version of the SLEDAI, skin symptoms, mucosal ulcers and proteinuria were considered active only if they occurred for the first time or recurred. SLEDAI-2K scores points for the presence of rash, alopecia, mucosal ulcers and proteinuria > 0.5 g/day and also when they persist chronically. The patient receives points if the symptom appeared in the last 10-30 days. A maximum of 105 points can be obtained (Table I) [14].

Based on SLEDAI-2K, the definition of remission, low disease activity (LDA) and high disease activity (HDA) was established. Remission is considered the absence of clinical symptoms of SLE (with or without serological signs), in patients without treatment or taking anti-malarial drugs. Low disease activity is considered SLEDAI-2K < 3 (with positive or negative serological tests) with only one clinical sign present, with a score range of 1 to 2, in patients taking antimalarials (without glucocorticosteroids [GCs] and other immunosuppressants). High disease activity is a SLEDAI 2K score > 6 (Table II) [15].

According to Carter et al., one can divide SLE activity based on SLEDAI-2K into severe (SLEDAI-2K > 12), moderate ($6 < \text{SLEDAI-2K} \leq 12$), mild ($0 < \text{SLEDAI-2K} \leq 6$) and remission (SLEDAI-2K = 0) [16]. A clinical variation of the SLEDAI scale in clinical practice (clinical SLEDAI-2K – cSLEDAI-2K) is being used increasingly. It does not take into account the results of serological tests (concentration of anti-dsDNA, C3 and/or C4 complement) but does take into account the use of antimalarial drugs, low doses of GCs, and immunosuppressive drugs, including biologics. In some SLE patients, immune activity may persist for a long time despite clinical inactivity. According to many researchers, such a condition does not increase the risk of SLE exacerbation [17–20].

Values obtained on the SLEDAI-2K scale are a measure of total SLE activity and a good predictor of mortality. Its significant advantage is the facility and speed of filling, which allows it to be widely used in clinical settings. Disadvantages of this scale may include: a fixed score of individual SLE symptoms (a patient with thrombocytopenia of $50,000/\mu\text{l}$ receives 1 point, as does a patient with a score of $3,000/\mu\text{l}$), inability to assess the degree of improvement or worsening of clinical symptoms, and failure to take into account other symptoms of SLE, including hemolytic anemia, pneumonia and gastrointestinal symptoms [14, 21].

The SELENA-SLEDAI scale is applicable to premenopausal women taking oral contraceptives and postmenopausal women taking hormone replacement therapy. The SELENA-SLEDAI assesses the same 24 clinical symptoms as in the original SLEDAI scale that are present at the time of the visit or within the past 10 days. The SELENA-SLEDAI (like the SLEDAI-2K) also takes into account chronically persistent skin lesions [22, 23].

The Mex-SLEDAI scale was developed by Mexican researchers in 1992. It is a simplified version of the original SLEDAI scale. Some clinical manifestations of SLE, such as fatigue and lymphopenia, were added to it and others (lupus headache and visual disturbances) were removed. The Mex-SLEDAI scale does not take into account the results of laboratory tests, i.e. complement components or anti-dsDNA antibodies. A maximum score of 32 can be obtained and a score ≥ 5 indicates active disease. The sensitivity of this scale is 87.5% and specificity is 100%. Evaluation of SLE activity using Mex-SLEDAI is significantly less expensive compared to the classic SLEDAI scale [13].

General assessment of disease activity by the doctor – Physician Global Assessment

The PGA scale is a tool for estimating overall disease activity that is intended to allow the physician to present information about disease activity found at the time of the current evaluation using a Visual Analogue Scale (VAS).

The evaluation should be carried out by a physician, taking into account clinical activity, the functioning of various organs and systems, values of laboratory indicators and radiological data [24].

The activity determined by the PGA includes the following:

- 0 – lack of activity,
- 0.5–1 – mild activity,
- 1–2 – moderate activity,
- 2–3 – severe illness.

The PGA scale has high reliability when used by rheumatology specialists. It is sensitive to changes in

Table I. SLEDAI-2K descriptors and scores [14]

Weight	Description	Definition
8	Seizure	Recent onset, exclude metabolic, infectious or drug causes
8	Psychosis	Altered ability to function in normal activities caused by severe disturbances in the perception of reality. Includes hallucinations, incoherence, marked mental association, impoverished thinking content, marked loss of logical thinking, or catatonia. Uremia and drug-induced symptoms should be excluded
8	Organic brain syndrome	Altered mental function with impaired orientation, memory or other intellectual functions, with rapid onset and fluctuations in the severity of clinical symptoms; includes eclipse of consciousness with decreased ability to focus attention and inability to maintain attention and at least two of the following symptoms: impaired perception, incoherent speech, insomnia or daytime sleepiness, increased or decreased psychomotor activity. Symptoms caused by metabolic disorders, infection or medication should be excluded
8	Visual disturbance	Retinal changes of SLE. These include cytooid bodies, retinal hemorrhage, serous or hemorrhagic exudate into the choroid, or optic neuritis. Hypertension, infection or drug effects should be excluded
8	Cranial nerve disorder	Recent onset of sensory or motor neuropathy involving the cranial nerves
8	Lupus headache	Severe, persistent headache, which can be migrainous, but does not resolve after narcotic analgesia
8	Cerebrovascular stroke	Recent onset of cerebrovascular accidents. Atherosclerosis should be excluded
8	Vasculitis	Ulceration, gangrene, tender nodules on the fingers, periungual infarctions, splinter hemorrhage or vasculitis confirmed by biopsy or angiogram
4	Arthritis	≥ 2 joints – pain and features of inflammation (tenderness, swelling or effusion)
4	Myositis	Proximal muscle aching/weakness associated with elevated creatine kinase/aldolase activity or with electromyogram changes, or biopsy result indicating myositis
4	Urinary casts	Heme-granular or red blood cell casts
4	Hematuria	> 5 erythrocytes in the field of view when evaluating urine sediment; exclude stones, infection and other causes
4	Proteinuria	> 0.5 g/24 hours
4	Pyuria	> 5 leukocytes in the field of view, when evaluating urine sediment; exclude infection
2	Rash	Inflammatory type rash
2	Alopecia	Abnormal, patchy or diffuse loss of hair
2	Mucosal ulcers	Oral or nasal ulcerations
2	Pleuritis	Pleuritic chest pain with pleural rub or pleural effusion or pleural thickening
2	Pericarditis	Pain accompanied by at least one of the following: rubbing, effusion, confirmation of pericarditis on electrocardiogram or ultrasound
2	Low complement	Decreased levels of complement components C3, C4 or impaired CH50 hemolytic activity
2	Increased DNA binding	Increased DNA binding in the Farr test above the standard for laboratory tests
1	Fever	> 38°C; exclude infections
1	Thrombocytopenia	< 100,000/mm ³ ; exclude drug causes
1	Leukopenia	< 3,000/mm ³ ; exclude drug causes

Table II. Definitions of SLE activity based on SLEDAI-2K [15]

SLE activity	SLEDAI-2K	SLE treatment
Remission	No clinical signs ± serological signs of SLE	No treatment or antimalarial drugs
Low disease activity – LDA	SLEDAI-2K < 3 points ± serological symptoms and one clinical symptom of SLE with a max. score of 1 or 2 points according to SLEDAI-2K	Antimalarial drugs, without GCs and other immunosuppressants
High disease activity – HDA	SLEDAI 2K > 6 points	Any treatment

GCs – glucocorticosteroids, SLE – systemic lupus erythematosus, SLEDAI-2K – Systemic Lupus Erythematosus Disease Activity Index 2000.

activity and comprehensively takes into account all aspects of the disease. The PGA has been shown to be associated with permanent damage arising in the course of SLE. Disadvantages of PGA include the subjectivity of assessment and lack of standardization.

Despite its drawbacks, the PGA is rated as a good tool for assessing changes in disease activity and a good indicator of disease exacerbation. The PGA scale is incorporated into various systems for assessing the response to therapy such as DORIS and LLDAS.

Systemic Lupus Erythematosus Disease Activity Score

An increasingly used tool for assessing SLE activity is the SLE-DAS index, which is based on the SLEDAI-2K scale. It was developed and validated by Jesus et al. in 2019. These researchers conducted a cohort study involving 520 SLE patients. Disease activity was assessed using the SLEDAI-2K scale and PGA, which was the dependent variable in the SLE-DAS construct. This indicator was validated in another cohort, taking into account the correlations occurring between PGA, SLEDAI-2K and SLE-DAS. The problem in assessing disease activity in the scales available to date has been the inability to distinguish between disease remission and LDA. Therefore, it was proposed to include a physician's assessment of PGA disease activity in conjunction with laboratory results and clinical evaluation. The study showed a strong correlation of SLE-DAS with PGA ($r = 0.875$, $p < 0.0005$) and SLEDAI-2K ($r = 0.943$, $p < 0.0005$). The SLE-DAS had higher sensitivity in detecting significant clinical improvement or worsening compared to the SLEDAI-2K scale (89.5% vs. 47.4%, $p = 0.008$ and 95.5% vs. 59.1%, $p = 0.008$, respectively), as well as a higher predictive value of damage accrual. An important factor contributing to this difference was the use of ongoing measurements of arthritis severity, proteinuria, thrombocytopenia and leukopenia in the SLE-DAS. A limitation of the above study was PGA, which was a subjective assessment by the physician. In the SLE-DAS, compared to the SLEDAI-2K, the number of scored symptoms was reduced from 24 to 17 and clinically significant symptoms were added, including: hemolytic anemia, gastrointestinal disorders, peritonitis, and cardiac/lung involvement (Table III) [25, 26]. This seems particularly relevant in the male population, which is more likely to have cardiac involvement and hemolytic anemia in the course of SLE [27]. Subsequent studies have confirmed a significant correlation between SLEDAI-2K and SLE-DAS. In patients with low SLE activity, the SLE-DAS index showed higher sensitivity and specificity compared to SLEDAI-2K [25, 28].

The SLE-DAS scale is distinguished by the variability of the value of an indicator depending on the degree

of disease activity, which allows for more precise monitoring of SLE activity. This includes symptoms such as arthritis, proteinuria, leukopenia and thrombocytopenia. A complex mathematical formula is used to calculate the SLE-DAS, and in clinical practice the use of a calculator is essential [29]. The advantage of the SLE-DAS index is its easy availability (online) and the short time it takes to conduct an assessment of disease activity. A limitation of the SLE-DAS is the assessment of renal parameters based on proteinuria only; SLEDAI-2K additionally considers sterile leukocyturia, hematuria, urinary casts and fever.

Based on SLE-DAS values, the following categories of SLE activity were developed: remission, mild, low and moderate/severe disease activity (Table IV). Disease activity categories in the SLE-DAS are easy to define and only require an SLE-DAS assessment during an ongoing medical visit. The sensitivity and specificity of using the SLE-DAS to assess remission, mild and moderate/severe SLE activity were 90%, 82% and 95%, respectively [30, 31].

Assessment of SLE activity in pregnant women

A modification of the SLEDAI scale used to assess SLE activity in pregnant women is the Systemic Lupus Erythematosus Pregnancy Disease Activity Index (SLEPDAI) [32]. Pregnancy is known to lead to physiological changes that can be interpreted in pregnant women with SLE as symptoms of an exacerbation of the autoimmune disease (e.g., edema, proteinuria, skin lesions). The SLEPDAI scale assesses the same clinical and immunological parameters as the basic variant of the SLEDAI scale, but attention should be paid to physiological changes in the pregnant woman's body that may resemble symptoms of SLE exacerbation (Table V) [33].

A high SLEPDAI score correlates with an increased risk of complications in a pregnant SLE patient and her child. There was a significant correlation between SLEPDAI and the occurrence of preeclampsia/pregnancy eclampsia, preterm labor, and low neonatal birth weight (Table VI) [34–37]. The SLEPDAI scale has not yet been fully validated, and further research is needed to confirm its reliability. The SLE-DAS is also used to assess SLE activity in pregnant women. Larosa et al. assessed SLE activity in pregnant women during the first trimester of pregnancy using the SLE-DAS and SLEPDAI. They found a strong correlation between these indicators ($r = 0.97$, $p < 0.01$). Both of these scales also predicted the appearance of complications at later stages of pregnancy [38]. Both the SLEPDAI and SLE-DAS scales are simple and effective in assessing SLE exacerbations in pregnant women and in predicting pregnancy complications. It appears that SLE-DAS may be preferable due to its ease of use and continuous evaluation capabilities.

Table III. The SLE-DAS: clinical and laboratory parameters attributable to SLE [25]

Manifestation	Description
1. Arthritis	Number of swollen joints in 28-joint count
2. Localized skin rash	Acute, subacute and chronic cutaneous lupus rashes included in the SLICC classification criteria, only above the neck
3. Generalized skin rash	Acute, subacute and chronic cutaneous lupus rashes included in the SLICC classification criteria, above and below the neck
4. Alopecia	Abnormal, patchy or diffuse loss of hair
5. Mucosal ulcers	Oral or nasal ulcerations
6. Systemic vasculitis	Systemic vasculitis involving large and medium-sized vessels and lupus enteritis
7. Mucocutaneous vasculitis	Any mucocutaneous vasculitis and chilblain lupus
8. Neuropsychiatric involvement	Neuropsychiatric features included in the SLICC classification criteria for SLE, including recent onset of seizure, psychosis, organic brain syndrome, acute confusional state, SLE retinal changes, peripheral neuropathy, myelopathy, lupus headache, cerebrovascular accident and aseptic meningitis
9. Cardiac/pulmonary involvement	Including shrinking lung, interstitial pneumonitis, diffuse alveolar hemorrhage, pulmonary hypertension, myocarditis, valvular dysfunction, Libman-Sacks endocarditis
10. Serositis	Including sterile peritonitis in addition to pleurisy and pericarditis
11. Myositis	Proximal muscle aching/weakness with elevated CK/aldolase or electromyogram changes or a biopsy showing myositis
12. Proteinuria	Urinary protein-creatinine ratio (mg/g) or 24-hour urinary protein (mg/24 hours), above 500 mg/g and 500 mg/24 hours, respectively
13. Hypocomplementaemia	Decrease in C3 or C4 below the lower limit of normal for laboratory testing
14. Increased anti-dsDNA	Increase in DNA binding above the upper limit of normal for laboratory testing
15. Thrombocytopenia	Platelet count ($10^9/l$), below $100 \times 10^9/l$ platelets
16. Leucopenia	Leukocyte count ($10^9/l$), below $3 \times 10^9/l$ white blood cells
17. Hemolytic anemia	Anemia with positive direct Coombs test, increased serum LDH and low serum haptoglobin

CK – creatine kinase, LDH – lactic dehydrogenase, SLE – systemic lupus erythematosus, SLICC – Systemic Lupus International Collaborating Clinics.

Table IV. SLE-DAS disease activity categories [30]

SLE-DAS disease activity category	Disease activity
SLE-DAS > 7.64	Moderate/severe disease activity
$2.08 < \text{SLE-DAS} \leq 7.64$	Mild disease activity
SLE-DAS ≤ 2.48	Low disease activity

SLE – systemic lupus erythematosus, SLE-DAS – Systemic Lupus Erythematosus Disease Activity Score.

Use of activity scales to assess remission and low systemic lupus erythematosus activity

The goal of SLE treatment is to achieve remission or low disease activity. In 2016, Franklyn et al. presented a definition of the lupus low disease activity state – LLDAS of SLE [39]:

1. SLEDAI-2K ≤ 4 points, with the absence of activity in major organs/systems (kidney, central nervous system, cardiopulmonary system, vasculitis, fever) and the absence of hemolytic anemia and active gastrointestinal inflammation.

2. No new signs of disease activity compared to previous examination.
3. PGA value < 1.
4. Current dose of prednisone or equivalent dose of other GCs ≤ 7.5 mg/day.
5. Good tolerance of maintenance doses of immunosuppressant or biologic drugs.

In 2016, as part of the operation of the so-called DORIS initiative, a definition of remission in SLE was established [40]. The current, updated version of the DORIS criteria is from 2021 and includes the following criteria:

1. SLEDAI-2K = 0.
2. PGA < 0.5.

Table V. SLEPDAI descriptors [33]

Score	Descriptor	Modified for pregnancy	Considerations
8	Seizure	Yes	r/o eclampsia
8	Psychosis	No	
8	Organic brain syndrome	No	
8	Visual disturbance	No	Hypertension is already considered an exclusion in SLEDAI
8	Cranial nerve disorder	Yes	r/o Bell palsy
8	Lupus headache	Yes	r/o Bell palsy
8	CVA	Yes	r/o eclampsia
8	Vasculitis	Yes	Consider palmar erythema
4	Arthritis	Yes	Consider bland knee effusions
4	Myositis	No	
4	Urinary casts	No	
4	Hematuria	Yes	r/o cystitis and vaginal RBC reflective of placental problems
4	Proteinuria	Yes	r/o eclampsia
4	Pyuria	Yes	r/o infection
2	Rash	Yes	Consider chloasma
2	Alopecia	Yes	Consider normal postpartum alopecia
2	Mucosal ulcers	No	
2	Pleurisy	Yes	Hyperventilation may be secondary to progesterone, dyspnea secondary to enlarging uterus
2	Pericarditis	No	
2	Low complement	Yes	Complement levels normally rise during pregnancy
2	Increased DNA binding	No	
1	Thrombocytopenia	Yes	r/o preeclampsia, HELLP syndrome, incidental thrombocytopenia of pregnancy
1	Leukopenia	Yes	Consider normal rise of leukocyte count during pregnancy
1	Fever	No	

CVA – cerebrovascular accident, HELLP – HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, r/o – rule out, SLEDAI – Systemic Lupus Erythematosus Disease Activity Index.

Table VI. Relationships between SLEPDAI and pregnancy complications in women with SLE – results of selected retrospective studies [34–37]

Author	Results of the study
Çetin et al. [34]	Higher SLEPDAI score correlated with increased risk of fetal/neonatal death, premature labor due to pre-eclampsia/pregnancy eclampsia, HELLP syndrome, low neonatal birth weight
Murata et al. [35]	SLEPDAI > 4 significantly correlated with risk of premature labor and pre-eclampsia
Erazo-Martínez et al. [36]	Higher SLEPDAI score significantly correlated with the risk of pre-eclampsia and eclampsia of pregnant women
Ignacchiti Lacerda et al. [37]	SLEPDAI ≥ 4 correlated with low birth weight of newborns

HELLP – HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, SLEPDAI – Systemic Lupus Erythematosus Pregnancy Disease Activity Index.

3. Good tolerance of treatment with antimalarial drugs, prednisone < 0.5 mg/day or equivalent, and/or an immunosuppressant or biologic [41].

Both definitions use the SLEDAI-2K scale score, demonstrating the importance of this scale in assessing

prognosis and treatment planning. Pawlak-Buś et al. found that the strongest predictor of remission according to DORIS and LLDAS was the mean SLEDAI-2K score. The lower the SLEDAI-2K value was, the higher was the chance of achieving remission or low disease activity.

The authors found that in untreated SLE patients, SLEDAI-2K ≤ 8 was a significant predictor of DORIS and LLDAS goal achievement ($p < 0.001$ and $p < 0.001$, respectively). In treated patients, a SLEDAI-2K value ≤ 12.5 was the most important predictor of these targets (DORIS $p = 0.004$ and LLDAS $p = 0.002$) [42]. In clinical practice, the evaluation of SLE treatment efficacy should be measured with an easy and objective tool. According to Saccon et al. the goal of SLE treatment is to achieve SLEDAI-2K = 0. This value correlates with a low probability of organ damage in remission lasting at least 2 years, regardless of the PGA value. The authors noted that achieving SLEDAI-2K = 0 preceded the achievement of PGA < 0.5 . This was likely due to the presence of symptoms such as fatigue or joint pain, which affected PGA but did not affect SLEDAI-2K values or organ damage [43].

Two criteria for remission have been proposed, based on the SLE-DAS scale score. The first criterion defines SLE remission in patients with SLE-DAS ≤ 2.08 taking prednisone ≤ 5 mg/day. The second criterion is based on the Boolean index: achieving a score of 0 in all SLE-DAS clinical domains and a daily dose of prednisone ≤ 5 mg. The criterion for remission based on the SLE-DAS index value is a cumulative score and reflects overall disease activity, thus giving some flexibility in assessing individual symptoms. The Boolean index is more stringent, requiring low values in each test domain present at the same time. Both SLE-DAS remission criteria were found to be comparable to DORIS clinical remission criteria. The SLE-DAS has the advantage of being easy to use – it does not require PGA or specific recommendations for antimalarials, immunosuppressants or biologics [26]. Remission according to the SLE-DAS shows 100% concordance with DORIS criteria. Low SLE activity according to the SLE-DAS (SLE-DAS ≤ 2.48 and prednisolone dose ≤ 7.5 mg/day) showed more than 97% agreement with LLDAS. The criteria for remission and LDA based on the SLE-DAS index are easier to apply compared to the DORIS and LLDAS definitions [44].

However, some researchers consider that a more effective tool for LDA and SLE remission is the SLE-DAS rather than the SLEDAI scale. Assunção et al. reported that a certain percentage of those meeting LLDAS criteria still had active arthritis (1%), skin lesions (1.4%) or mucosal ulcers (0.4%). None of these individuals met the LDA criterion of the SLE-DAS, which would suggest the greater sensitivity of this scale in assessing low disease activity [45]. Cunha et al. found that as many as 7.5% of SLE patients with SLEDAI ≤ 4 did not reach the LDA criterion according to the SLE-DAS [46]. Shumilova et al. in a study of 228 SLE patients found that the SLEDAI-2K scale had higher specificity than the SLE-DAS for assessing SLE remission (89% and 79%, respectively),

but the SLE-DAS was more specific than the SLEDAI-2K for assessing low disease activity (80% and 59%, respectively) [47].

The SLE-DAS has been shown to have some advantage over the SLEDAI-2K in assessing the risk of hospitalization for SLE and other causes. A prospective cohort study involving 326 Taiwanese patients showed that SLE patients with moderate/severe disease activity according to the SLE-DAS had a significantly higher risk of hospitalization for SLE as well as for other causes. The SLEDAI-2K value showed no significant correlation with the risk of hospitalization for SLE exacerbation and only a slight association with hospital admissions for other reasons [48]. Similarly, Wang et al. found that patients with moderate/severe SLE activity according to the SLE-DAS index were more likely to be hospitalized for both general and SLE-related causes. Moderate or severe activity according to SLEDAI-2K was only significantly associated with hospitalization of SLE patients for general causes [49]. This difference can be explained by the inclusion of heart/lung involvement in the course of SLE in the SLE-DAS compared to SLEDAI-2K.

Summary

Reliable assessment of SLE activity is key to making treatment decisions. In clinical practice, we particularly often use the SLEDAI-2K scale. More and more data are confirming the usefulness of the SLE-DAS index. Both tools are of comparable value in assessing SLE activity and complement each other.

Acknowledgments

We want to thank Natalia Wilczek, Kacper Niewęglowski, and Mateusz Suszek, students from The Student Scientific Circle at the Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland for their commitment and support.

Disclosures

Conflict of interest: The authors declare no conflict of interest.

Funding: No external funding.

Ethics approval: Not applicable.

Data availability: Not applicable.

References

1. Lazar S, Kahlenberg JM. Systemic Lupus erythematosus: new diagnostic and therapeutic approaches. *Annu Rev Med* 2023; 74: 339–352, DOI: 10.1146/annurev-med-043021-032611.

2. Pawlak-Buś K, Schmidt W, Dudzic E, Leszczyński P. Current treatment of systemic lupus erythematosus: a clinician's perspective. *Rheumatol Int* 2023; 43: 1395–1407, DOI: 10.1007/s00296-023-05306-5.
3. Panagiotis A, Lambros A. Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus. *Life* 2023; 13: 1496, DOI: 10.3390/life13071496.
4. Zucchi D, Cardelli C, Elefante E, et al. Treat-to-target in systemic lupus erythematosus: reality or pipe dream. *J Clin Med* 2023; 12: 3348, DOI: 10.3390/jcm12093348.
5. Castrejón I, Rúa-Figueroa I, Rosario MP, Carmona L. Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. *Reumatol Clin* 2014; 10: 309–320, DOI: 10.1016/j.reuma.2014.01.012.
6. Carter LM, Gordon C, Yee CS, et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. *Rheumatology (Oxford)* 2022; 61: 4006–4015, DOI: 10.1093/rheumatology/keab883.
7. Cruciani C, Zen M, Gatto M, et al. Assessment of disease activity and damage in SLE: Are we there yet? *Best Pract Res Clin Rheumatol* 2023; 12: 101896, DOI: 10.1016/j.berh.2023.101896.
8. Parra Sánchez AR, van Vollenhoven RF, Morand EF, et al. Targeting DORIS Remission and LLDAS in SLE: A Review. *Rheumatol Ther* 2023; 10: 1459–1477, DOI: 10.1007/s40744-023-00601-w.
9. Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? *Semin Arthritis Rheum* 2019; 48: 1035–1040, DOI: 10.1016/j.semarthrit.2018.10.013.
10. Pitsigavdaki S, Nikoloudaki M, Garantziotis P, et al. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. *Ann Rheum Dis* 2024; 12: 83: 464–474, DOI: 10.1136/ard-2023-224919.
11. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A Disease Activity Index for Lupus Patients. *Arthritis Rheum* 1992; 35: 630–640, DOI: 10.1002/art.1780350606.
12. Stajszczyk M, Majdan M, Kwiatkowska B, et al. Systemic lupus erythematosus in Poland – medical and social aspects of the disease and treatment strategy. Polish Society of Rheumatology, Warsaw 2023. Available at: <https://reumatologia.ptr.net.pl/files/raport-toczen-rumieniowaty-ukladowy-w-polsce-2023.pdf> (Access: 27.12.2023).
13. Uribe AG, Vilá LM, McGwin G Jr, et al. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. *J Rheumatol* 2004; 31: 1934–1940.
14. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002; 29: 288–291.
15. Arora S, Isenberg DA, Castrejón I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. *Arthritis Care Res (Hoboken)* 2020; 72 Suppl 10: 27–46, DOI: 10.1002/acr.24221.
16. Carter EE, Barr SG, Clarke AE. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. *Nat Rev Rheumatol* 2016; 12: 605–620, DOI: 10.1038/nrrheum.2016.137.
17. Pawlak-Buś K, Leszczyński P. 2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists. *Reumatologia* 2022; 60: 125–132, DOI: 10.5114/reum.2022.115667.
18. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. *Arthritis Care Res (Hoboken)* 2012; 64: 511–518, DOI: 10.1002/acr.21568.
19. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. *J Rheumatol* 2010; 37: 1822–1827, DOI: 10.3899/jrheum.100007.
20. Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. *Autoimmun Rev* 2016; 15: 656–663, DOI: 10.1016/j.autrev.2016.02.019.
21. Leilei Y, Bingjie Gu, Xiaoqin W, et al. Association of disease activity with depression and anxiety in systemic lupus erythematosus: A comparison of SLEDAI-2K and SLE-DAS. *Rheumatology (Oxford)* 2024, DOI: 10.1093/rheumatology/keae070.
22. Ohmura K. Which is the best SLE activity index for clinical trials? *Mod Rheumatol* 2021; 31: 20–28, DOI: 10.1080/14397595.2020.1775928.
23. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. *Arthritis Res Ther* 2015; 17: 183, DOI: 10.1186/s13075-015-0702-6.
24. Piga M, Chessa E, Morand EF, et al. Physician Global Assessment International Standardisation Consensus in Systemic Lupus Erythematosus: the PISCOS study. *Lancet Rheumatol* 2022; 4: e441–e449, DOI: 10.1016/S2665-9913(22)00107-2.
25. Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. *Ann Rheum Dis* 2019; 78: 365–371, DOI: 10.1136/annrheumdis-2018-214502.
26. Koo M, Lu MC. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS. *Medicina (Kaunas)* 2023; 59: 2097, DOI: 10.3390/medicina5912209725.
27. Ramírez Sepúlveda JI, Bolin K, Mofors J, et al. Sex differences in clinical presentation of systemic lupus erythematosus. *Biol Sex Differ* 2019; 10: 60, DOI: 10.1186/s13293-019-0274-226.
28. Lai NS, Lu MC, Chang HH, et al. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life. *J Clin Med* 2021; 10: 2137, DOI: 10.3390/jcm10102137.
29. SLE Disease Activity Score Calculator. Available at: <http://sle-das.eu/> (Access: 23.12.2023).
30. Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate

- and user-friendly definitions of clinical remission and categories of disease activity. *Ann Rheum Dis* 2021; 80: 15681574, DOI: 10.1136/annrheumdis-2021-220363.
31. Abdelhady EI, Rabie M, Hassan RA. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). *Clin Rheumatol* 2021; 40: 4553–4558, DOI: 10.1007/s10067-021-05803-7.
 32. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. *Lupus* 1999; 8: 677–684, DOI: 10.1191/096120399680411272.
 33. Pastore DEA, Costa ML, Parpinelli MA, Surita FG. A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus. *Rev Bras Ginecol Obstet* 2018; 40: 209–224, DOI: 10.1055/s-0038-1625951.
 34. Çetin Ç, Saraç-Sivrikoz T, Ateş-Tıkız M, et al. The correlation between pregnancy, disease activity and adverse pregnancy outcomes in patients with systemic lupus erythematosus. *Lupus* 2023; 32: 1509–1517, DOI: 10.1177/09612033231208844.
 35. Murata T, Kyojuka H, Fukuda T, et al. Maternal disease activity and serological activity as predictors of adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective chart review. *Arch Gynecol Obstet* 2022; 305: 1177–1183, DOI: 10.1007/s00404-021-06148-x.
 36. Erazo-Martínez V, Nieto-Aristizábal I, Ojeda I, et al. Systemic erythematosus lupus and pregnancy outcomes in a Colombian cohort. *Lupus* 2021; 30: 2310–2317, DOI: 10.1177/09612033211061478.
 37. Ignacchiti Lacerda M, Costa Rodrigues B, Ramires de Jesus G, et al. The association between active proliferative lupus nephritis during pregnancy and small for gestational age newborns. *Clin Exp Rheumatol*. 2021; 39: 1043–1048, DOI: 10.55563/clinexprheumatol/xspect.
 38. Larosa M, Costedoat-Chalumeau N, Guettrot-Imbert G, et al. SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy. *Front Pharmacol* 2021; 12: 660123, DOI: 10.3389/fphar.2021.660123.
 39. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). *Ann Rheum Dis* 2016; 75: 1615–1621, DOI: 10.1136/annrheumdis-2015-207726.
 40. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis* 2017; 76: 554–561, DOI: 10.1136/annrheumdis-2016-209519.
 41. van Vollenhoven RF, Bertsias G, Doria A, et al. DORIS definition of remission in SLE: final recommendations from an international task force. *Lupus Sci Med* 2021; 8: e000538, DOI: 10.1136/lupus-2021-000538.
 42. Pawlak-Buś K, Schmidt W, Leszczyński P. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes. *Eur Rev Med Pharmacol Sci* 2023; 27: 949–959, DOI: 10.26355/eurrev_202302_31188.
 43. Saccon F, Zen M, Gatto M, et al. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. *Ann Rheum Dis* 2020; 79: 943–950, DOI: 10.1136/annrheumdis-2020-217070.
 44. Inês LS, Fredi M, Jesus D, et al. What is the best instrument to measure disease activity in SLE? – SLE-DAS vs Easy BILAG. *Autoimmun Rev* 2024; 23: 103428, DOI: 10.1016/j.autrev.2023.103428.
 45. Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. *Rheumatology (Oxford)* 2022; 61: 3309–3316, DOI: 10.1093/rheumatology/keab895.
 46. Cunha RN, Saraiva L, Jesus D, et al. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up. *Rheumatology (Oxford)* 2023; 62: 3627–3635, DOI: 10.1093/rheumatology/kead097.
 47. Shumilova A, Cheldieva F, Reshetnyak T. Miscellaneous conditions associated with SLE LP-118 Assessment of systemic lupus erythematosus activity and remission: SLEDAI-2k or SLE-DAS – which to choose? *Lupus Sci Med* 2023; 10, DOI: 10.1136/lupus-2023-KCR.214.
 48. Lu MC, Hsu CW, Koo M, Lai NS. Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: a prospective cohort study. *Clin Exp Rheumatol*. 2023; 41: 1409–1416, DOI: 10.55563/clinexprheumatol/2z3tyc.
 49. Wang CL, Koo M, Hsu CW, Lu MC. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study. *Lupus* 2023; 32: 864–872, DOI: 10.1177/09612033231175268.